CJC-1295 with DAC – 5mg/vial (Research Use Only)

Overview

CJC-1295 with DAC is a long-acting synthetic GHRH analogue modified with a Drug Affinity Complex (DAC) — a reactive succinimidyl moiety at lysine-36 that forms a covalent amide bond with circulating albumin, substantially extending plasma half-life from minutes to approximately 6–8 days. This pharmacokinetic profile makes it the primary subject in published research examining sustained pituitary GHRH receptor stimulation, contrasting with the short-acting CJC-1295 (No DAC) variant used in pulsatile GH axis studies.

What It Is

CJC-1295 with DAC is a 30-amino acid GHRH analogue incorporating four amino acid substitutions for DPP-IV resistance (positions 2, 8, 15, 27) and a DAC reactive linker at Lys-30 enabling covalent albumin binding after administration. Molecular weight of the unconjugated form: approximately 3,647 Da. CAS number: 863288-34-0. The albumin-bound form produces an effective half-life of approximately 6–8 days in published animal pharmacokinetic models.

Research Spotlight

CJC-1295 with DAC has been investigated in published research as a model for chronic, sustained GHRH receptor stimulation — contrasting with the pulsatile GH release patterns characteristic of short-acting GHRH analogues. Research has examined IGF-1 axis plateau dynamics, pituitary somatotroph desensitization kinetics, and body composition parameters in GH-axis animal models over extended administration periods. Pharmacokinetic studies have characterized albumin-binding kinetics, half-life extension chemistry, and bioavailability of the covalently modified form. Comparative research between CJC-1295 (No DAC) and CJC-1295 (with DAC) has examined differences in GH pulse patterns, IGF-1 response curves, and tissue-level outcomes in animal preparations, providing a mechanistic framework for studying short-acting versus long-acting GHRH receptor agonism.

Key Research Applications

• Long-acting GHRH receptor agonism and sustained pituitary GH secretion modeling
• Chronic GH axis activation and IGF-1 response plateau pharmacodynamics research
• Pharmacokinetic comparison of short-acting vs. long-acting GHRH analogues
• Albumin-reactive covalent drug affinity complex half-life extension chemistry research
• Sustained GH stimulation and pituitary desensitization modeling
• IGF-1 axis response to continuous vs. pulsatile GHRH stimulation studies
• Body composition and adipose tissue research in GH axis animal models
• DPP-IV resistance modification pharmacology in GHRH analogue research

For laboratory research use only. Not intended for human or veterinary use, medical diagnosis, treatment, or prevention of any disease or condition. This product has not been evaluated by the FDA or any regulatory agency. Must be handled by qualified research personnel in a compliant laboratory setting.

Not sure which compounds fit your research? Browse the Research Hub →

Related research (educational)

• Overlapping Pathways in Circadian, Repair and Mitochondrial Biology